Combining GLP-1 therapies with amylin analogues and metabolic enhancers like SLM+ may offer a synergistic approach to weight loss. STAAR LABS’ research provides insights into optimizing GLP-1 therapy outcomes.
Adding Pramlintide to GLP-1 Therapies
- Liraglutide + Pramlintide: Liraglutide (11-18 lbs) combined with pramlintide (5-12 lbs) may achieve 20-24 lbs over 52 weeks. Pramlintide enhances satiety and stabilizes blood sugar, complementing GLP-1’s appetite suppression.*
- Dulaglutide + Pramlintide: Dulaglutide (11-15 lbs) with pramlintide may achieve 16-20 lbs, offering similar synergistic effects.*
Using SLM+ in Conjunction
- Liraglutide + Pramlintide + SLM+: Initial research suggests this combination may support 33-46 lbs over 52 weeks, potentially matching tirzepatide’s efficacy (33-46 lbs) while remaining 503A-compliant. SLM+ may enhance endogenous GLP-1 production, mimic GIP’s metabolic role, and support fat oxidation.*
- Dulaglutide + Pramlintide + SLM+: May support 29-42 lbs, surpassing Dulaglutide + Pramlintide alone (16-20 lbs) and offering a legal alternative to semaglutide (22-33 lbs).*
The Power of Synergy
Combining GLP-1 therapies with amylin analogues and metabolic enhancers like SLM+ may address the limitations of standalone GLP-1s, providing a safe, legal option in the post-shortage landscape.* This approach may help patients achieve greater weight loss while managing side effects like fatigue.
Collaborate with STAAR LABS
STAAR LABS welcomes partnerships with pharmacies and providers to explore similar synergistic protocols. Contact us at info@staarlabs.com to learn more.
Stay updated on STAAR LABS’ research. Join our community for insights into optimizing GLP-1 therapy outcomes at STAAR LABS
Legal Disclaimer: These statements have not been evaluated by the Food and Drug Administration (FDA). The information provided is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. SLM+ Gen 2 is in development and not yet available; projected benefits are subject to change pending final results (expected June 2025). Always consult a healthcare provider before starting any new therapy or supplement, especially if using GLP-1 therapies or managing medical conditions. STAAR LABS is not responsible for adverse effects resulting from use.
